Q-omics provides the consensus-scored KPNA5 profile across patient tissues and cancer cell-line models. KPNA5 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, KPNA5 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, KPNA5 RNA expression shows 21,523 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UCS, KICH, and KIRP as cancer lineages where KPNA5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KPNA5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KPNA5 survival associations across molecular data types. KPNA5 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KPNA5 RNA expression–survival associations across cancer types. High KPNA5 expression shows unfavorable associations in LIHC and OV, but favorable associations in UCS, SKCM, LGG and LUAD. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for KPNA5 RNA expression.
This table summarizes KPNA5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for KPNA5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KPNA5 shows lower tumor expression in KICH, THCA, LUSC, LUAD, UCEC and BRCA. The KICH box plot shows higher KPNA5 RNA expression in normal versus tumor tissue (log2 FC = −1.381, t-test p < 0.001).
This table shows molecular features associated with KPNA5 in patient tissues and cancer cell lines. In patient samples, KPNA5 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, KPNA5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
